HC Wainwright Predicts Armata Pharmaceuticals FY2026 Earnings

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Free Report) – Stock analysts at HC Wainwright upped their FY2026 earnings per share estimates for shares of Armata Pharmaceuticals in a research note issued on Friday, November 13th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of $2.63 per share for the year, up from their previous estimate of $0.50. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Armata Pharmaceuticals’ current full-year earnings is $0.50 per share. HC Wainwright also issued estimates for Armata Pharmaceuticals’ Q4 2026 earnings at ($0.51) EPS and FY2027 earnings at ($1.92) EPS.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.32. Armata Pharmaceuticals had a negative net margin of 1,626.27% and a negative return on equity of 33.09%. The company had revenue of $3.17 million during the quarter, compared to analyst estimates of $0.45 million.

Armata Pharmaceuticals Price Performance

Armata Pharmaceuticals stock opened at $2.99 on Tuesday. The firm’s 50 day simple moving average is $3.74 and its 200-day simple moving average is $6.83. Armata Pharmaceuticals has a fifty-two week low of $2.74 and a fifty-two week high of $14.98.

Institutional Investors Weigh In On Armata Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Madison Asset Management LLC acquired a new position in Armata Pharmaceuticals in the 1st quarter worth approximately $21,583,000. BlackRock Inc. acquired a new stake in Armata Pharmaceuticals during the 2nd quarter valued at $3,629,000. Sei Investments Co. acquired a new stake in Armata Pharmaceuticals during the 1st quarter valued at $760,000. Empowered Funds LLC acquired a new stake in Armata Pharmaceuticals during the 3rd quarter valued at $149,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Armata Pharmaceuticals in the second quarter valued at $193,000. Hedge funds and other institutional investors own 3.57% of the company’s stock.

About Armata Pharmaceuticals

(Get Free Report)

Armata Pharmaceuticals is a clinical-stage biotechnology company developing bacteriophage-based treatments for bacterial infections. Bacteriophages are viruses that infect and kill specific bacteria, and Armata’s approach is intended to target disease-causing bacteria, including strains that are difficult to treat with antibiotics. The company’s development programs have included AP-PA02, an inhaled phage therapy being studied for Pseudomonas aeruginosa lung infections, and AP-SA02, an intravenous therapy targeting Staphylococcus aureus infections.

Featured Stories

Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.